Plasma sPD-L1 and VEGF levels are associated with the prognosis of NSCLC patients treated with combination immunotherapy
Sign Up to like & getrecommendations! Published in 2024 at "Anti-Cancer Drugs"
DOI: 10.1097/cad.0000000000001576
Abstract: The clinical significance of plasma soluble programmed cell death ligand 1 (sPD-L1) and vascular endothelial growth factor (VEGF) for non-small cell lung cancer (NSCLC) treated with the combination of anti-angiogenic therapy and anti-PD-L1 antibody (Ab)… read more here.
Keywords: spd vegf; nsclc patients; vegf levels; treated combination ... See more keywords